Ectopic expression of B and T lymphocyte attenuator in gastric cancer: A potential independent prognostic factor in patients with gastric cancer

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 658-664

  Feng, Xing Yu ^a   Wen, Xi Zhi ^a   Tan, Xiao Jing ^b,c   Hou, Jing Hui ^a   Ding, Ya ^a   Wang, Ke Feng ^a   Dong, Jun ^a   Zhou, Zhi Wei ^a   Chen, Ying Bo ^a   Zhang, Xiao Shi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Third Affiliated Hospital   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

B and T lymphocyte attenuator; Gastric cancer; Prognosis; Survival rate

Indexed keywords

FLUOROURACIL; BTLA PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADICAL RESECTION; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOMA; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR VOLUME; AGED; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; STOMACH NEOPLASMS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; STOMACH NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84916242923     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2699     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Ajani JA, Barthel JS, Bekaii-Saab T, et al; NCCN Gastric Cancer Panel: Gastric cancer. J Natl Compr Canc Netw 8: 378-409, 2010.
4. Park do J, Kong SH, Lee HJ, et al: Subclassifcation of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery 141: 757-763, 2007.
5. Liu X, Xu Y, Long Z, Zhu H and Wang Y: Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol 16: 1875-1882, 2009.
6. Bretscher PA: A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 96: 185-190, 1999.
7. Chambers CA and Allison JP: Costimulatory regulation of T cell function. Curr Opin Cell Biol 11: 203-210, 1999.
8. Chambers CA, Kuhns MS, Egen JG and Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594, 2001.
9. Barber DL, Wherry EJ, Masopust D, et al: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687, 2006.
10. Peggs KS, Quezada SA and Allison JP: Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224: 141-165, 2008.
11. Ha SJ, West EE, Araki K, Smith KA and Ahmed R: Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 223: 317-333, 2008.
12. Blackburn SD, Shin H, Haining WN, et al: Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29-37, 2009.
13. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
14. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
15. Eggermont AM and Robert C: New drugs in melanoma: it's a whole new world. Eur J Cancer 47: 2150-2157, 2011.
16. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
17. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133, 2013.
18. Watanabe N, Gavrieli M, Sedy JR, et al: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4: 670-679, 2003.
19. Sedy JR, Gavrieli M, Potter KG, et al: B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6: 90-98, 2005.
20. Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al: A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 102: 1116-1121, 2005.
21. Derré L, Rivals J P, Jandus C, et al: BTLA mediates inhibition of human tumor-specifc CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 120: 157-167, 2010.
22. Fu Z, Li D, Jiang W, et al: Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province. Breast Cancer Res Treat 120: 195-202, 2010.
23. Sobin LH, Gospodarowicz MK and Wittekind C: International Union Against Cancer (UICC) TNM classifcation of malignant tumours. 7. New York: Wiley-Liss, 2010.
24. Japanese Gastric Cancer Association: Japanese Classifcation of Gastric Carcinoma-2nd English Edition. Gastric Cancer 1: 10-24, 1998.
25. Ajani JA, Barthel JS, Bekaii-Saab T, et al; NCCN Gastric Cancer Panel: Gastric cancer. J Natl Compr Canc Netw 8: 378-409, 2010.
26. Wang W, Lv L, Pan K, et al: Reduced expression of transcription factor AP-2α is associated with gastric adenocarcinoma prognosis. PLoS One 6: e24897, 2011.
27. Gavrieli M, Sedy J, Nelson CA and Murphy KM: BTLA and HVEM cross talk regulates inhibition and costimulation. Adv Immunol 92: 157-185, 2006.
28. Salvi S, Fontana V, Boccardo S, et al: Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 61: 1463-1472, 2012.
29. Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is consti-tutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117: 538-550, 2005
30. Mao H, Zhang L, Yang Y, et al: New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 10: 728-736, 2010.
31. Zhuang X, Zhang X, Xia X, et al: Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol 137: 978-985, 2012.
32. Dong J, Li J, Liu SM, et al: CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. Med Oncol 30: 442, 2013.
33. Fourcade J, Sun Z, Pagliano O, et al: CD8(+) T cells specifc for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72: 887-896, 2012.
34. Pasero C and Olive D: Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol Lett 151: 71-75, 2013.